Tetrathiomolybdate in Hormone Refractory Prostate Cancer

NCT00150995 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Tetrathiomolybdate

Sponsor

University of Michigan Rogel Cancer Center